Overview

Nasopharyngeal Carcinoma (NPC) Axitinib

Status:
Completed

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

This is an open-label, single arm, phase 2 clinical trial evaluating the activity and safety of single-agent axitinib in recurrent or metastatic NPC patients who failed at least one line of platinum based chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Chinese University of Hong Kong

Treatments:

Axitinib